At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery Patients Randomized to Different Postoperative Anticoagulant Regimens
In Brief
A Phase 2 clinical trial evaluating Fixed dose and Variable dose for Venous Thromboembolism and 3 related conditions. Completed, enrolled 295 participants across 2 sites.
Detailed Summary
Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their operative procedures. Thus, plastic \& reconstructive surgery patients are among those at highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). This study seeks to optimize both the safety and effectiveness of post-operative enoxaparin by comparing aFXa levels, bleeding events, and VTE events among plastic \& reconstructive surgery patients randomized to receive two different enoxaparin dose regimens.
Study Details
Timeline
Interventions
Participants will receive 40 mg enoxaparin twice daily
Participants will receive 0.5mg/kg enoxaparin twice daily